Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Dr. Galsky on the Rationale of the CheckMate 274 Trial in Urothelial Carcinoma

May 24th 2022

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial cancer.

Sacituzumab Govitecan Under Further Exploration in Metastatic Urothelial Cancer

May 19th 2022

Sacituzumab govitecan will be further evaluated in patients with locally advanced unresectable or metastatic urothelial cancer that has progressed after prior platinum or checkpoint inhibitor therapy, as a part of the phase 3 TROPiCS-04 trial.

A Widening Scope of Treatment Options Advances Care in Bladder Cancer and RCC

May 18th 2022

Mark T. Fleming, MD, reviews the use of first-line checkpoint inhibitors in bladder cancer, the efficacy of enfortumab vedotin-ejfv in urothelial cancer, and the clinical benefits of using different mechanisms of action to treat renal cell carcinoma.

Dr. Grivas on the Future of the TROPHY U-01 Regimen in Urothelial Cancer

May 17th 2022

Petros Grivas, MD, PhD, discusses the future of the phase 2 TROPHY U-01 trial regimen in metastatic urothelial cancer.

Toripalimab Produces Promising Clinical Activity in Metastatic Urothelial Cancer

May 17th 2022

The recombinant humanized anti–PD-1 monoclonal antibody toripalimab elicited an encouraging objective response rate with an acceptable toxicity profile in patients with metastatic urothelial cancer who were refractory to frontline chemotherapy.

Immunotherapy Plus Nadofaragene Firadenovec Could Display Synergistic Activity in NMIBC

May 17th 2022

Nadofaragene firadenovec combined with immune checkpoint inhibitors such as pembrolizumab may play a synergistic role in the treatment of patients with Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer.

Antegrade Administration of Mitomycin Gel Provides Safe, Effective Approach in Upper Tract Urothelial Carcinoma

May 16th 2022

Data from a retrospective analysis demonstrated that mitomycin gel was safe and effective when administered using an antegrade approach in real-world populations of patients with low-grade upper tract urothelial cancer.

Neoadjuvant Tislelizumab/Nab-Paclitaxel Combo Produces Early Activity in MIBC

May 16th 2022

The combination of neoadjuvant tislelizumab and nab-paclitaxel elicited a high rate of pathologic complete response in patients with muscle-invasive bladder cancer, according to preliminary findings from the phase 2 TRUCE-01 trial.

Frontline Nivolumab/Ipilimumab Misses OS End Point in PD-L1+ Unresectable or Metastatic Urothelial Carcinoma

May 16th 2022

The combination of nivolumab plus ipilimumab was not found to significantly improve overall survival over standard-of-care chemotherapy when used in the first-line treatment of patients with unresectable or metastatic urothelial carcinoma with a PD-L1 expression of 1% or higher.

Dr. Ghali on Nectin-4 and TROP-2 Expression in Urothelial, Variant Histology Bladder Cancer

May 16th 2022

Fady Ghali, MD, discusses the expression of Nectin-4 and TROP-2 in variant histology bladder cancer and urothelial cancer.

TROP-2, Nectin-4 Are Highly Expressed in Urothelial, Variant Histology Bladder Cancer

May 16th 2022

TROP-2 and Nectin-4, surface cell targets of sacituzumab govitecan and enfortumab vedotin, respectively, are highly expressed in urothelial cancer and variant histology bladder cancer.

Infigratinib Generates Activity in FGFR-Mutated Urothelial Carcinoma

May 16th 2022

Infigratinib yielded notable activity and tolerability in patients with localized upper tract urothelial carcinoma harboring FGFR1/2/3 mutations.

Quality of Life Is Maintained With Mitomycin Gel in Low-Grade Non–Muscle Invasive Bladder Cancer

May 16th 2022

Patients with low-grade non-muscle invasive bladder cancer who received the chemoablative reverse thermal gel UGN-102 were found to have maintained health-related quality-of-life outcomes.

Dr. Mitra on Nadofaragene Firadenovec Plus Anti–PD-1 Therapy in BCG-Unresponsive NMIBC

May 16th 2022

Anirban P. Mitra, MD, PhD, discusses data from an assessment of PD-1 and PD-L1 status on transurethral resection specimens collected from patients with non–muscle-invasive bladder cancer who received nadofaragene firadenovec as part of a phase 3 trial.

Co-Treatment With Vitamin C Increases Therapeutic Effect of Chemotherapy in Cisplatin-Ineligible MIBC

May 15th 2022

Cisplatin-ineligible patients with locally advanced muscle invasive bladder cancer undergoing chemotherapy may benefit from simultaneous treatment with intravenous vitamin C.

Dr. Galsky on Updated CheckMate 274 Data With Adjuvant Nivolumab in Urothelial Carcinoma

May 15th 2022

Matthew Galsky, MD, discusses long-term data from the phase 3 CheckMate 274 trial evaluating adjuvant nivolumab vs placebo in patients with high-risk, muscle-invasive urothelial cancer.

Up-Front Avelumab Maintenance Improves OS in Urothelial Carcinoma

May 14th 2022

Avelumab plus best supportive care produced a benefit in overall survival in patients with advanced urothelial carcinoma that had not progressed with first-line platinum-based chemotherapy.

Dr. Khetrapal on Intracorporeal Robotic vs Open Cystectomy in MIBC

May 14th 2022

Pramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.

Nivolumab Offers Long-Term DFS Benefits in Urothelial Carcinoma

May 14th 2022

According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.

N-803 Plus BCG Produces Clinically Meaningful Benefit in BCG-Unresponsive Bladder Cancer

May 13th 2022

The addition of the IL15RaFc superagonist N-803 to Bacillus Calmette–Guérin led to prolonged complete responses and disease-free survival (DFS) in patients with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ and papillary histology, respectively.